<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364338</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2398-502X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Wellcome open research</Title><ISOAbbreviation>Wellcome Open Res</ISOAbbreviation></Journal><ArticleTitle>VIVALDI Cohort Profile: Using linked, routinely collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related outcomes in care home staff and residents in England.</ArticleTitle><Pagination><StartPage>553</StartPage><MedlinePgn>553</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">553</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/wellcomeopenres.20278.2</ELocationID><Abstract><AbstractText>VIVALDI (ISRCTN14447421) is a government-funded longitudinal open observational cohort study of staff and residents in care homes for older people in England. The study aimed to describe epidemiology (including seroprevalence) and immune responses to COVID-19 in a subset of care homes, in the context of extremely high mortality in this setting, in the first 12-18 months of the pandemic. Data linkage to routine health data was undertaken for all staff and residents and a subset of individuals who consented to sequential blood sampling to investigate SARS-CoV-2 immunity. This paper aims to describe the samples stored within the VIVALDI biobank and associated linked data, available for use by researchers. Over 70,000 individuals from 346 care homes were included in the data linkage cohort (1 <sup>st</sup> March 2020-31 <sup>st</sup> March 2023). 4971 samples from 2264 individuals (1415 staff, 827 residents) collected between 29 <sup>th</sup> October 2020 and 10 <sup>th</sup> March 2023 are stored. Amongst these samples, there was a maximum of seven per participant however, 217 (26.2%) residents and 551 (38.9%) staff participated in one round only. Key study findings include high COVID-19 seroprevalence among surviving residents, exceeding rates in community-dwelling peers. COVID-19 vaccinations generated robust immune responses in staff and residents which waned, supporting the need for booster vaccination, particularly in response to new variants. Prior infection significantly improved vaccine-induced immune responses, however protection from infection declined following Omicron variant emergence. This is a unique cohort of pre- and post-infection samples linked to data on COVID-19 infections, vaccinations, and outcomes. The cohort spans host immune response evolution to infection and vaccination in this rarely sampled population of frail older care home residents who are especially vulnerable to infection and severe outcomes. These samples can be used to investigate biological mechanisms behind disparate infection responses in older people and make a valuable contribution to research into ageing.</AbstractText><CopyrightInformation>Copyright: © 2024 Krutikov M et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krutikov</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3982-642X</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, England, NW1 2DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bone</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stirrup</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8705-3281</Identifier><AffiliationInfo><Affiliation>Institute for Global Health, University College London, London, England, WC1N 1EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruton</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azmi</LastName><ForeName>Borscha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, England, NW1 2DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, England, NW1 2DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>May</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Juliet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastogi</LastName><ForeName>Shivika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monakhov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, London, SW1P 3JR, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tut</LastName><ForeName>Gokhan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infection &amp; Immunity, University College London, London, England, WC1E 6JF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6895-1967</Identifier><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3549-6232</Identifier><AffiliationInfo><Affiliation>Institute of Epidemiology &amp; Health Care, University College London, London, England, WC1E 7HB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, England, NW1 2BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Copas</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Global Health, University College London, London, England, WC1N 1EH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shallcross</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1713-2555</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, England, NW1 2DA, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University College Hospitals London NHS Trust, NIHR Biomedical Research Centre, London, NW1 2PG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Wellcome Open Res</MedlineTA><NlmUniqueID>101696457</NlmUniqueID><ISSNLinking>2398-502X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">care homes</Keyword><Keyword MajorTopicYN="N">data linkage</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">older adults</Keyword></KeywordList><CoiStatement>Competing interests: LS, AC, AH, and OS report grants from the Department of Health &amp; Social Care and the UK Health Security Agency (UKHSA) during the conduct of the study and LS is a member of the Social Care Working Group, which reports to the Scientific Advisory Group for Emergencies. AH reports funding from the COVID Core Studies Programme and is a member of the New and Emerging Respiratory Virus Threats Advisory Group at the Department of Health and Environmental Modelling Group of the Scientific Advisory Group for Emergencies. No other competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364338</ArticleId><ArticleId IdType="pmc">PMC11447437</ArticleId><ArticleId IdType="doi">10.12688/wellcomeopenres.20278.2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krutikov M, Palmer T, Donaldson A, et al. : Study Protocol: understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI) [version 2; peer review: 2 approved]. Wellcome Open Res. 2020;5:232. 10.12688/wellcomeopenres.16193.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16193.2</ArticleId><ArticleId IdType="pmc">PMC7851710</ArticleId><ArticleId IdType="pubmed">33564722</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bell D, Comas-Herrera A, Henderson D, et al. :
COVID-19 mortality and long-term care: a UK comparison. 2020; (accessed May 10, 2023).
Reference Source
</Citation></Reference><Reference><Citation>
GOV.UK:
COVID-19 surveillance and immunity studies up to March 2023. 
2023; (accessed Aug 17, 2023).
Reference Source
</Citation></Reference><Reference><Citation>
GOV.UK:
Whole home testing rolled out to all care homes in England. 
2020; (accessed Feb 18, 2022).
Reference Source
</Citation></Reference><Reference><Citation>Mohanraj D, Bicknell K, Bhole M, et al. : Antibody responses to SARS-CoV-2 infection—comparative determination of seroprevalence in two high-throughput assays versus a sensitive spike protein ELISA. Vaccines (Basel). 2021;9(11): 1310. 10.3390/vaccines9111310</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111310</ArticleId><ArticleId IdType="pmc">PMC8624239</ArticleId><ArticleId IdType="pubmed">34835241</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson AV, Weaving G, Philips BJ, et al. : Real-world experience of SARS-CoV-2 antibody assays in UK healthcare workers. Clin Med (Lond). 2021;21(3):e300–5. 10.7861/clinmed.2020.1007</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020.1007</ArticleId><ArticleId IdType="pmc">PMC8140713</ArticleId><ArticleId IdType="pubmed">33727368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth M, Andersson M, Auckland K, et al. : Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390–400. 10.1016/S1473-3099(20)30634-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30634-4</ArticleId><ArticleId IdType="pmc">PMC7511171</ArticleId><ArticleId IdType="pubmed">32979318</ArticleId></ArticleIdList></Reference><Reference><Citation>
GOV.UK:
COVID-19 care home testing guidance for regular and outbreak testing of staff and residents. 
2022; (accessed Feb 18, 2022).
Reference Source
</Citation></Reference><Reference><Citation>
NHS England:
Statistics » COVID-19 Vaccinations. 
2022; (accessed Jan 21, 2022).
Reference Source
</Citation></Reference><Reference><Citation>
NHS Digital:
Hospital Episode Statistics (HES). 
2022; (accessed Jan 21, 2022).
Reference Source
</Citation></Reference><Reference><Citation>
NECS:
Capacity Tracker. 
2022; (accessed Jan 21, 2022).
Reference Source
</Citation></Reference><Reference><Citation>
Coronavirus (COVID-19) scaling up our testing programmes. DHSC.2020.
Reference Source
</Citation></Reference><Reference><Citation>
Fotaki M, Horton A, Rowland D, et al. :
Bailed out and burned out? The financial impact of COVID-19 on UK care homes for older people and their workforce. Coventry,2023; (accessed May 16, 2023).
Reference Source
</Citation></Reference><Reference><Citation>Gateway to Global Aging Data: Surveys at a Glance. 2020; (accessed Aug 17, 2023).</Citation></Reference><Reference><Citation>
Abell J, David Batty G, Bennett G, et al. :
Wave 9: The dynamics of ageing evidence from the english longitudinal study of ageing 2002-2019.
2020; (accessed Aug 17, 2023).
Reference Source
</Citation></Reference><Reference><Citation>Hewitt J, Walters M, Padmanabhan S, et al. : Cohort profile of the UK biobank: diagnosis and characteristics of cerebrovascular disease. BMJ Open. 2016;6(3): e009161. 10.1136/bmjopen-2015-009161</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-009161</ArticleId><ArticleId IdType="pmc">PMC4809076</ArticleId><ArticleId IdType="pubmed">27006341</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Herrera VM, Lown M, Fisk HL, et al. : Relationships between age, frailty, length of care home residence and biomarkers of immunity and inflammation in older care home residents in the United Kingdom. Front Aging. 2021;2: 599084. 10.3389/fragi.2021.599084</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fragi.2021.599084</ArticleId><ArticleId IdType="pmc">PMC9261419</ArticleId><ArticleId IdType="pubmed">35821989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AL, Franklin M, Bradshaw L, et al. : Health status of UK care home residents: a cohort study. Age Ageing. 2014;43(1):97–103. 10.1093/ageing/aft077</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/aft077</ArticleId><ArticleId IdType="pmc">PMC3861334</ArticleId><ArticleId IdType="pubmed">23864424</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze A, Nightingale E, Evans D, et al. : Mortality among care home residents in England during the first and second waves of the COVID-19 pandemic: an observational study of 4.3 million adults over the age of 65. Lancet Reg Health Eur. 2022;14: 100295. 10.1016/j.lanepe.2021.100295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100295</ArticleId><ArticleId IdType="pmc">PMC8743167</ArticleId><ArticleId IdType="pubmed">35036983</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver D: David Oliver: let’s be open and honest about covid-19 deaths in care homes. BMJ. 2020;369: m2334. 10.1136/bmj.m2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2334</ArticleId><ArticleId IdType="pubmed">32554433</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics:
Changes in the older resident care home population between 2001 and 2011. 
2014; (accessed Sept 15, 2023).
Reference Source
</Citation></Reference><Reference><Citation>
Skills for Care:
Care homes with nursing in the adult social care sector 2021/22.2022; (accessed Sept 15, 2023).
Reference Source
</Citation></Reference><Reference><Citation>
Forder J, Fernandez JL:
Length of stay in care homes.2011; (accessed July 12: 2021).
Reference Source
</Citation></Reference><Reference><Citation>Steventon A, Roberts A: Estimating length of stay in publicly-funded residential and nursing care homes: a retrospective analysis using linked administrative data sets. BMC Health Serv Res. 2012;12: 377. 10.1186/1472-6963-12-377</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-12-377</ArticleId><ArticleId IdType="pmc">PMC3537534</ArticleId><ArticleId IdType="pubmed">23110445</ArticleId></ArticleIdList></Reference><Reference><Citation>
Skills for Care:
The state of the adult social care sector and workforce in England.2022; (accessed March, 2023).
Reference Source
</Citation></Reference><Reference><Citation>Krutikov M, Palmer T, Tut G, et al. : Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev. 2022;3(1):e13–21. 10.1016/S2666-7568(21)00282-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00282-8</ArticleId><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tut G, Lancaster T, Sylla P, et al. : Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of Long-Term Care Facilities: an observational cohort study. Lancet Healthy Longev. 2022;3(7):e461–9. 10.1016/S2666-7568(22)00118-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00118-0</ArticleId><ArticleId IdType="pmc">PMC9252532</ArticleId><ArticleId IdType="pubmed">35813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tut G, Lancaster T, Butler MS, et al. : Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection. Nat Aging. 2022;2(6):536–47. 10.1038/s43587-022-00224-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00224-w</ArticleId><ArticleId IdType="pmc">PMC10154219</ArticleId><ArticleId IdType="pubmed">37118449</ArticleId></ArticleIdList></Reference><Reference><Citation>Tut G, Lancaster T, Krutikov M, et al. : Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. Lancet Healthy Longev. 2021;2(9):e544–53. 10.1016/S2666-7568(21)00168-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00168-9</ArticleId><ArticleId IdType="pmc">PMC8376213</ArticleId><ArticleId IdType="pubmed">34430954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tut G, Lancaster T, Krutikov M, et al. : Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. Nat Aging. 2023;3(1):93–104. 10.1038/s43587-022-00328-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00328-3</ArticleId><ArticleId IdType="pmc">PMC10154221</ArticleId><ArticleId IdType="pubmed">37118525</ArticleId></ArticleIdList></Reference><Reference><Citation>Stirrup O, Krutikov M, Tut G, et al. : Severe acute respiratory syndrome coronavirus 2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 vaccine in residents of long-term care facilities in England (VIVALDI). J Infect Dis. 2022;226(11):1877–81. 10.1093/infdis/jiac146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac146</ArticleId><ArticleId IdType="pmc">PMC9047242</ArticleId><ArticleId IdType="pubmed">35429382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>